Objectives: To assess the feasibility of axillary transcatheter aortic valve implantation (TAVI) using the Lotus valve.
and subsequently using the Sapien valve (Edwards, USA) [14] . Evidence is emerging that the transaxillary (subclavian) route is safe [15] . Observational data have demonstrated that survival following axillary access is not significantly different from survival following TF access while survival following transaortic/transapical access was significantly lower than TF and axillary access [16, 17] .
The Lotus System (Boston Scientific, USA) is a 2nd generation transcatheter heart valve approved for use in Europe in October 2013
and currently under evaluation in the USA. It is fully repositionable and retrievable, designed to facilitate precise delivery [18] and has excellent results at 1 year, particularly in minimizing para-valvular aortic regurgitation [19] . This is particularly important as moderate or greater paravalvular regurgitation is associated with increased mortality following TAVI [5, 20] . Initially implanted via the femoral route, the valve is now licensed for transaortic access also. The Lotus valve is currently not licensed in Europe for transaxillary access although there is one report of the Lotus valve being delivered successfully via the axillary artery [21] . All patients underwent a gated cardiac multidetector CT (MDCT) and helical MDCT of the aorta and ilio-femoral vessels. All patients were assessed by the Heart Team as being unsuitable for open heart surgery.
| M E TH ODS
Between
| Lotus valve
The Lotus valve consists a woven, nitinol wire, self-expanding frame to which is mounted a bovine pericardial aortic valve and is designed for catheter-based introduction. The valve is expanded via controlled mechanical expansion. Rapid pacing is not required during valve deployment; the valve functions early in the deployment cycle and can be repositioned or fully retrieved at any point before uncoupling and valve release. An outer adaptive seal is designed to minimize paravalvu- 
| Axillary access
The left axillary artery was considered suitable for TAVI with the 
| Statistical methods
The populations were described using median and interquartile range for continuous variables and percentage for categorical variables. 
| RE S U L TS

| Baseline demographics
Baseline demographics are shown in Table 1 .
Patients who received transaortic/transapical TAVI had significantly higher Logistic Euroscore than the patients undergoing TF TAVI (19 vs 14; p0.001). Logistic Euroscore was also numerically higher in the entire axillary cohort compared with the TF group, although this did not meet significance (22 vs 14; p 5 0.07). The transaortic/transapical and entire axillary group more frequently had peripheral vascular disease than the TF cohort (p < 0.001). 
| Procedural characteristics
The majority of femoral TAVI cases were carried out under local anaesthetic whilst all transaxillary cases and all transaortic/transapical cases were performed under general anaesthetic. The rates of postdilatation and choice of TAVI valve used can also be seen in Table 2 .
| Outcomes
Procedural outcomes are shown in Table 3 .
Device success, defined according to the Valve Academic Research Consortium-2 (VARC-2) consensus document [22] , was high in the whole cohort with the valve implanted successfully in 99% of patients. In the entire population rates of major complications including in-hospital death (4.7%), 30-day mortality (4.4%), peri-procedural MI (1.6%), peri-procedural stroke (0.8%), and major access site complications (2.3%) were low (all according to VARC-2).
The requirement for permanent pacing post-TAVI and before discharge was 7.4%.
All 10 patients undergoing transaxillary with Lotus required a 20F sheath for a 25 or 27 mm valve. The sheath was successfully passed into the ascending aorta in nine patients. In one patient, the tip of the sheath would not pass an area of calcification in the proximal axillary artery, however, the delivery sheath, being of narrower diameter, successfully traversed the obstruction and the valve was deployed uneventfully. There was no haemodynamic instability or ECG evidence of ischaemia in any of the four patients with patent IMAs during the procedure following introduction of the sheath. Procedural success was achieved in all patients. Passage of the Lotus THV to the native aortic valve was uncomplicated in all patients. Due to the short distance from the access site to the native aortic valve and as the catheter was delivered in a "2" configuration, the catheter naturally self-oriented and proved extremely easy to deliver. Postimplant valve gradients were low and no patient required valvuloplasty postvalve deployment. Four of the 10 patients (40%) required a pacemaker because of heart block. In all cases pacing was undertaken in the theatre room prior to skin closure if high degree atrioventricular block occurred and persisted for more than 20 minutes after valve deployment. None of these patients had pre-existing conduction abnormalities such as right bundle branch block or first-degree heart block on electrocardiogram. There were no major vascular complications or access site related problems in any of the 10 patients. Two patients with morbid obesity (BMI 40 and 47) were extubated on ITU. The remaining eight patients were extubated immediately after TAVI in the catheter laboratory and then transferred directly to the coronary care unit. Patients were able to mobilize quickly after the procedure. The median length of stay was significantly lower in the entire axillary group compared with the transapical/transaortic group (3 days vs 7 days, P < 0.001). Significantly more patients in the transaortic/transapical group (28%) required blood transfusions than the Peak CRP and peak total CPK were both significantly higher in the transapical/transaortic cohort compared with the entire axillary group. About 67% of patients in the transapical/transaortic group required a chest drain compared with 0% in the axillary group. access was associated with a higher need for blood transfusion than axillary access and these patients also usually required a chest drain immediately following the procedure. The greater invasiveness of transaortic/transapical access was reflected in the markedly higher peak CRP compared with the axillary cohort. CRP is a marker of the systemic inflammatory response [24] and a high CRP postcardiothoracic surgery is associated with a higher risk of major cardiovascular adverse events [25] .
Further evidence of the more invasive nature of transapical/transaortic access was the observation that these patients experienced longer lengths of stay both in the intensive care unit and in hospital compared to patients who underwent axillary TAVI. This has important beneficial implications of axillary access for both for patients, who enjoy a reduced hospital stay and healthcare providers by reducing overall costs.
| S TU D Y L I M I TA TI ONS
The main limitation of our study is that the cohort of patients who underwent axillary TAVI via the axillary artery was relatively small at 16 patients. A further limitation is that this is not a randomized study.
Finally, we do not yet have long-term follow-up data on the group of patients who had axillary TAVI using Lotus.
| C ONC LUSI ON
In our small cohort of patients, TAVI with the Lotus valve using a transaxillary approach was safe and had outcomes comparable to TAVI via the TF route. Patients who underwent transaxillary TAVI had significantly fewer complications and required a shorter hospital stay than those undergoing transaortic or direct apical procedures. Our data are consistent with the growing body of evidence that suggests axillary access is safer and less invasive than transaortic/transapical access and may be the preferred alternative access.
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